Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Editas Medicine, Inc. EDIT
$9.43
-$0.13 (-1.41%)
На 18:00, 12 мая 2023
+128.00%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
666497496.00000000
-
week52high
19.97
-
week52low
6.33
-
Revenue
19712000
-
P/E TTM
-3
-
Beta
1.85086500
-
EPS
-3.29000000
-
Last Dividend
0.00000000
-
Next Earnings Date
05 мая 2023 г. в 12:00
Описание компании
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Barclays | Equal-Weight | Equal-Weight | 04 авг 2022 г. |
| Goldman Sachs | Sell | Sell | 24 мая 2022 г. |
| Morgan Stanley | Underweight | Underweight | 09 мая 2022 г. |
| Morgan Stanley | Underweight | Underweight | 12 апр 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 25 февр 2022 г. |
| B of A Securities | Neutral | 29 сент 2022 г. | |
| Truist Securities | Buy | Buy | 18 ноя 2022 г. |
| Morgan Stanley | Underweight | Underweight | 18 ноя 2022 г. |
| B of A Securities | Neutral | Neutral | 18 ноя 2022 г. |
| Baird | Outperform | Outperform | 18 ноя 2022 г. |
| Morgan Stanley | Underweight | Underweight | 08 ноя 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 10 янв 2023 г. |
| Wells Fargo | Overweight | Overweight | 04 янв 2023 г. |
| Citigroup | Neutral | 13 дек 2022 г. | |
| Cantor Fitzgerald | Overweight | 01 февр 2023 г. | |
| Morgan Stanley | Underweight | Underweight | 24 янв 2023 г. |
| SVB Leerink | Market Perform | Market Perform | 23 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| ROBERTSON MICHELLE | D | 80530 | 1752 | 10 янв 2023 г. |
| Eaton Bruce | D | 64636 | 102 | 05 дек 2022 г. |
| ROBERTSON MICHELLE | D | 82282 | 193 | 05 дек 2022 г. |
| Eaton Bruce | D | 64738 | 289 | 08 ноя 2022 г. |
| Eaton Bruce | D | 65027 | 101 | 06 сент 2022 г. |
| ROBERTSON MICHELLE | D | 82475 | 192 | 06 сент 2022 г. |
| Eaton Bruce | D | 65128 | 293 | 09 авг 2022 г. |
| Mei Baisong | A | 171602 | 171602 | 18 июл 2022 г. |
| Mei Baisong | A | 58372 | 58372 | 18 июл 2022 г. |
| Shearman Mark S | D | 68349 | 5145 | 15 июн 2022 г. |
Новостная лента
Editas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress
GlobeNewsWire
11 мая 2023 г. в 10:32
CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that a scientific abstract detailing safety and efficacy clinical data from the Phase 1/2 RUBY trial of EDIT-301 in patients with severe sickle cell disease has been accepted for an oral presentation at the European Hematology Association (EHA) Hybrid Congress being held June 8-11, 2023, in Frankfurt, Germany, and via live stream.
Editas (EDIT) Q1 Earnings Top, Pipeline in Focus, Stock Up
Zacks Investment Research
08 мая 2023 г. в 12:57
Editas Medicine (EDIT) stock climbs 12% on Friday and 7% in the pre-market hours today, after the company beat estimates for both earnings and revenues in first-quarter 2023. Pipeline progress in focus.
Editas Medicine, Inc. (EDIT) Q1 2023 Earnings Call Transcript
Seeking Alpha
05 мая 2023 г. в 14:30
Editas Medicine, Inc. (NASDAQ:EDIT ) Q1 2023 Results Conference Call May 5, 2023 8:00 AM ET Company Participants Cristi Barnett - Corporate Communications and IR Gilmore O'Neill - CEO Baisong Mei - Chief Medical Officer Michelle Robertson - CFO Conference Call Participants Joon Lee - Truist Securities Samantha Semenkow - Citi Dae Gon Ha - Stifel Steve Seedhouse - Raymond James Yanan Zhu - Wells Fargo Ernie Rodriguez - Cowen Rick Bienkowski - Cantor Fitzgerald Rich Law - Credit Suisse Ry Forseth - Guggenheim Luca Issi - RBC Capital Markets Cheng Li - Oppenheimer Operator Good morning, and welcome to Editas Medicine's First Quarter Conference Call. All participants are now in a listen-only mode.
Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
05 мая 2023 г. в 09:54
Editas Medicine (EDIT) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.74 per share a year ago.
Editas Medicine Announces First Quarter 2023 Results Conference Call and Upcoming Investor Events
GlobeNewsWire
01 мая 2023 г. в 06:45
CAMBRIDGE, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Friday, May 5, 2023, at 8:00 a.m. ET to discuss results for the first quarter 2023 and to provide a corporate update.